Filing Details
- Accession Number:
- 0000950170-25-003157
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-07 20:00:32
- Reporting Period:
- 2025-01-03
- Accepted Time:
- 2025-01-07 20:00:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1880438 | An2 Therapeutics Inc. | ANTX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1571820 | Sanjay Chanda | C/O An2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park CA 94027 | Chief Development Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2025-01-03 | 2,957 | $1.34 | 29,824 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025.
- Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
- Includes 2,224 shares purchased on March 31, 2024 under the Issuer's Employee Stock Purchase Plan ("ESPP") and 2,322 shares purchased on September 30, 2024 under ESPP in transactions exempt from reporting under Section 16(b)3.
Billionaire Hedge Funds
